Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib DDI with Rabeprazole and Rifampin in Healthy Subjects
NCT04510649Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Jul 2020
- Primary completion
- Sep 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of surufatinib in neuroendocrine tumors (NETs) (2 arms), sponsored by Hutchison MediPharma (HMP). Primary endpoints: Area Under the Plasma Concentration Time Curve and Maximum Plasma Concentration. Started Jul 2020; status: completed.
02
Drugs
surufatinib
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT04510649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04510649.